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Abstract
Microinjection of the calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-93
into the nucleus accumbens (NAcc) shell impairs expression of the sensitized locomotion and NAcc
dopamine (DA) overflow normally observed in psychostimulant-exposed rats. Based on these results,
we investigated the effect of NAcc shell KN-93 on the enhanced amphetamine (AMPH) intake
normally observed in AMPH- relative to saline-exposed rats. Rats were administered five injections
of either AMPH (1.5 mg/kg, i.p.) or saline, one injection every two-three days. Fourteen days
following the last injection, they were trained to self-administer AMPH (200 μg/kg/infusion, i.v.)
first on fixed ratio schedules (FR) and then on a progressive ratio schedule of reinforcement (PR).
As expected, AMPH-exposed rats worked harder and obtained significantly more drug infusions than
saline-exposed rats on the PR schedule. After four days of stable responding, all rats were bilaterally
microinjected with KN-93 (1 or 10 nmol/0.5 μl/side) into the NAcc shell, two minutes prior to the
beginning of the self-administration session. Inhibiting CaMKII in this site reduced the enhanced
drug intake observed in AMPH-exposed rats to levels no longer significantly different from those of
saline-exposed rats. Responding in these latter controls was not affected by KN-93 nor did KN-93
affect responding in AMPH-exposed rats when it was infused into the NAcc core. Thus, in a manner
similar to what has been reported for sensitized locomotion and NAcc DA overflow, these results
suggest that inhibiting CaMKII in the NAcc shell attenuates the enhanced motivation to obtain a drug
reinforcer that is normally displayed in AMPH-exposed rats.
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Repeated exposure to psychostimulants such as amphetamine (AMPH) enhances the ability of
these drugs to produce locomotor activation and nucleus accumbens (NAcc) dopamine (DA)
overflow, and also leads to enhanced drug taking [5,10,12,25,26,27]. These enhanced
responses, manifestations of behavioral and neurochemical sensitization, have been proposed
to model the transition from casual drug use to drug abuse and addiction [21,28]. Consistent
with this view, rats previously exposed to AMPH that work harder than saline-exposed controls
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to obtain the drug under a progressive ratio (PR) schedule of reinforcement also show enhanced
NAcc DA overflow compared to control animals [27].
The serine/threonine kinase CaMKII (calcium/calmodulin-dependent protein kinase II) is
required for the induction of LTP [9] and is known also to contribute importantly to the
induction [8] and expression (4,6,16,17) of sensitization by psychostimulants. CaMKII is
highly expressed in forebrain sites like the NAcc [3] and inhibiting its activity in this site blocks
the expression of sensitization by these drugs. While the acute effect of AMPH on DA release
is calcium (Ca2+)-independent, sensitized AMPH-induced NAcc DA overflow is dependent
on Ca2+ and is blocked by reverse dialysis of the CaMKII inhibitor KN-93 into the NAcc shell
[16]. Similarly, microinjecting KN-93 into this site attenuates sensitized locomotor responding
to cocaine [17]. KN-93 has also been shown to block sensitized AMPH-induced DA release
in synaptosomal [4] and striatal slice preparations [6] obtained from rats previously exposed
to AMPH. In addition to presynaptically regulating AMPH-induced DA overflow in the NAcc
and striatum, recent evidence suggests that CaMKII also postsynaptically mediates
psychostimulant-induced upregulation of AMPA receptors in medium spiny neurons of the
NAcc shell to facilitate the reinstatement of drug seeking [1].
Together, the above findings suggest that CaMKII may contribute to a number of
neuroadaptations resulting from exposure to AMPH, including sensitized locomotion and
NAcc DA overflow and the functional upregulation of NAcc AMPA receptors [24]. In light
of the evidence that exposure to AMPH also enhances AMPH self-administration, it is
conceivable that NAcc shell CaMKII contributes to this adaptation as well. The present
experiments assessed this possibility by investigating whether inhibiting CaMKII in the NAcc
shell alters the enhanced AMPH self-administration observed in sensitized rats.
Male Long-Evans rats (Harlan Teklad, Madison, WI) weighing 250–275 g upon arrival were
used. They were individually housed with food and water available at all times in a 12-h light/
12-h dark reverse cycle room. All experiments were conducted in accordance with the
Declaration of Helsinki and the Guide for the Care and Use of Laboratory Animals as adopted
and promulgated by the National Institutes of Health. All procedures were conducted according
to an approved IACUC protocol.
Starting 3–5 days after arrival, animals in different groups were administered a total of five
injections of AMPH (1.5 mg/kg, i.p.) or saline, one injection every 2–3 days. Similar drug
exposure regimens have been shown to result in robust sensitization of AMPH-induced
locomotion and NAcc DA overflow as well as enhanced AMPH self-administration [10,26,
27]. Two weeks after the last exposure injection, during which rats were surgically implanted
with an intravenous (i.v.) catheter [24] and chronic bilateral guide cannulae aimed at the NAcc
shell or core, AMPH self-administration training and testing was initiated. For all surgical
procedures, rats were anesthetized with a mix of ketamine (100 mg/kg, i.p.) and xylazine (6
mg/kg, i.p.). For intracranial implantation of cannulae, animals were placed in a stereotaxic
apparatus with the incisor bar positioned 5.0 mm above the interaural line and the guide
cannulae (22 gauge, Plastics One, Roanoke, VA) aimed at the NAcc shell (A/P, +3.4; L, ±0.8;
DV, −7.5) or core (A/P, +3.4;.L,±1.5; DV, −7.5). Coordinates are in mm from bregma and
skull [14]. Cannulae were angled at 10° to the vertical and positioned 1 mm above the final
injection site. Obturators (28 gauge) were placed in the guide cannulae and rats were returned
to their home cages. The i.v. catheters were implanted 5–7 days later using procedures generally
described previously [18]. These were made of silastic tubing (Dow Corning, Inc), inserted
into the right internal jugular vein, and positioned to exit slightly caudal of the midscapular
region. Catheters were subsequently flushed daily with a sterile 0.9% saline solution containing
30 IU/ml heparin and 250 mg/ml ampicillin in order to promote patency.
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Training for AMPH self-administration began 3 days after i.v. catheter implantation (14 days
after the final drug exposure injection and 8–10 days after implantation of the intracranial guide
cannulae). Ten test chambers (22 × 22 × 33 cm) containing a single retractable lever (5 cm
above the floor) and a stimulus light positioned 13.5 cm above the lever were used. Each
chamber was equipped with a counterbalanced arm, a steel-spring tether, and an infusion pump
(model A.E., Razel Scientific Inc., Stamford, CT) that allowed free movement of the animal
in the chamber and delivery of drug upon depression of the lever. Lever presses and drug
infusions were recorded and controlled via an electrical interface by a computer using locally
developed software. AMPH self-administration sessions were held daily and lasted for a
maximum of 3 h. In all cases, reinforced lever presses delivered an infusion of AMPH through
the i.v. catheter (200 μg/kg/infusion). An experimenter-delivered AMPH priming infusion was
given at the beginning of each session and rats were required to self-administer 10 infusions
of AMPH in a 3 hr session first on an FR1 and then an FR2 schedule of reinforcement. Animals
that did not satisfy each of the FR1 and the FR2 criteria within 5 days were excluded from the
study. Eight rats were thus excluded (AMPH-exposed, 2; saline-exposed, 6). Days to
satisfaction of the training criteria under each FR schedule were recorded. Five additional rats
were excluded due to nonpatent catheters or the development of leaks.
Upon satisfactory completion of training under the FR schedules, rats were tested daily under
a PR schedule of reinforcement for 7 days. Under this schedule, the number of responses
required to obtain each successive infusion of AMPH was determined by ROUND (5 × EXP
(0.25 × infusion number) − 5) to produce the following sequence of required lever presses: 1,
3, 6, 9, 12, 17, 24, 32, 42, 56, 73, 95, 124, 161, 208, etc [20]. The daily PR sessions were
terminated after 3 hr or after 1 hr elapsed without a drug infusion. Priming AMPH infusions
were not given on these sessions. On the first 4 sessions, rats received no NAcc infusion prior
to self-administration to establish enhanced AMPH self-administration in sensitized rats. On
the fifth PR session, rats were administered a bilateral microinjection of KN-93 into the NAcc
shell (1 or 10 nmol/0.5 μl/side) or, for control, the NAcc core (10nmol/0.5μl/side) over a period
of 1 minute with an additional minute to allow for diffusion. Doses were chosen based on
previous reports showing that 10 nmol/0.5μl/side KN-93 did not affect acute cocaine-induced
locomotion but selectively blocked the expression of sensitized locomotor responding to
cocaine [17]. Immediately after the microinjection, animals were allowed to self-administer
AMPH under the PR schedule. Finally, rats were tested on the remaining two sessions again
with no NAcc infusion prior to self-administration. The number of infusions obtained in each
PR session was recorded. S(+)-amphetamine sulfate (AMPH) was obtained from Sigma Inc.
(St. Louis, MO) and was dissolved in sterile 0.9% saline. KN-93 was obtained from
Calbiochem (San Diego, CA) and was dissolved in water.
At the end of the experiments, rats were anesthetized with sodium pentobarbital and perfused
with saline and 10% formalin. Coronal sections (40 μm) were mounted on gelatin-coated slides
and stained with cresyl violet for verification of cannulae tip placements. Only subjects with
both cannulae in the NAcc shell or in the NAcc core were included in the analyses (Fig. 1).
Eighteen rats were excluded for failing to meet this criterion (AMPH-exposed, 10; Saline-
exposed, 8). As reported by others [17], cannula tip placements in both the ventral and medial
limbs of the shell were included. There was no evidence to indicate that infusion into these two
sites within the NAcc shell produced differential effects. Statistical analyses were performed
according to Kirk [7].
Consistent with previous reports [10,27], rats previously exposed to AMPH (n=9) or saline
(n=8) similarly satisfied each of the FR1 and FR2 self-administration training criteria within
1–2 days. No significant group differences in days to criterion were detected with independent
samples t-tests for either ratio (t15=−0.16–1.38, NS). Again, consistent with previous reports
[10,27], rats previously exposed to AMPH worked more and obtained significantly more
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AMPH infusions under the PR schedule of reinforcement compared to saline-exposed controls.
This effect was maintained over the first 4 PR days of testing (Fig. 2). When number of
infusions obtained was analyzed with a between-within ANOVA with exposure (AMPH,
saline) as the between factor and days of testing (4) as the within factor, a significant effect of
exposure was detected (F1,15=8.76, P<0.01). This enhanced work output and self-
administration of AMPH in rats previously exposed to the drug was significantly reduced when
KN-93 (10nmol/0.5μl/side) was infused into the NAcc shell prior to self-administration on the
following PR test day. This infusion of KN-93 was without effect in saline-exposed controls
(Fig. 3). Comparing number of infusions obtained on PR test day 4 to those obtained on the
following KN-93 test day, a between-within ANOVA with exposure (AMPH, saline) as the
between factor and test days (PR4, KN-93) as the within factor detected a significant effect of
test days (F1,15=10.72, P<0.01) and a significant exposure by test days interaction (F1,15=7.58,
P<0.05). Post-hoc Scheffé comparisons revealed that AMPH-exposed rats obtained
significantly fewer AMPH infusions following NAcc shell KN-93 than on PR test day 4
(P<0.001). In addition, while AMPH-exposed rats obtained significantly more AMPH
infusions than saline-exposed rats on PR test day 4 (P<0.05), a significant difference between
groups was no longer detected on the KN-93 test day. In AMPH-exposed rats, responding
returned to pre-test levels following the KN-93 test day. The number of infusions obtained on
the two subsequent sessions (8.44±1.73 and 9.67±1.83) did not differ significantly from those
observed on PR test day 4 (t8=1.71 and 0.51, NS). In saline-exposed rats, responding did not
differ significantly from pre-test levels in these two sessions (5.50±1.51 and 7.5±1.66; t7=0.98
and 1.66, NS).
When a lower dose of KN-93 (1 nmol/0.5μl/side) was microinjected into the NAcc shell of
separate AMPH-exposed rats, the enhanced self-administration observed in these animals was
not significantly affected (Fig. 3 inset). Similarly, microinjection of 10nmol/side KN-93 into
the NAcc core of separate AMPH-exposed rats was without effect (Fig. 3 inset), suggesting
that CaMKII is acting in a site-specific manner to regulate enhanced drug self-administration.
When number of AMPH infusions obtained by these two groups on the KN-93 test day was
compared to that of AMPH-exposed rats administered 10 nmol/side KN-93 into the NAcc shell,
only the latter group showed a significant decrease relative to PR test day 4. A between-within
ANOVA with groups as the between factor (3) and test days (PR 4, KN-93) as the within factor
detected a significant groups by test days interaction (F2,18=4.91, P<0.05). Post-hoc Scheffé
comparisons revealed a significant decrease in AMPH infusions obtained from PR test day 4
to the KN-93 test day only in rats administered 10 nmol/side KN-93 into the NAcc shell
(P<0.001).
The present results show that inhibiting CaMKII in the NAcc shell decreases the enhanced
work output and AMPH self-administration normally observed in rats previously exposed to
the drug. This finding is consistent with those of previous reports showing that CaMKII
contributes to a number of pre-and postsynaptic neuroadaptations resulting from exposure to
AMPH, including sensitized NAcc DA overflow [16] and the functional upregulation of NAcc
AMPA receptors [24]. Both of these neuroadaptations have been linked to enhanced drug self-
administration and reinstatement [1,10,24,27], suggesting that the latter are behavioral
manifestations of CaMKII-dependent neuronal changes initiated by exposure to AMPH.
AMPH has been reported to produce sensitized locomotion and DA overflow preferentially in
the NAcc shell [15]. The present results showing that KN-93 was effective in the shell but not
the core of the NAcc are consistent with this finding and can be interpreted to suggest that
CaMKII influences the generation of sensitized behavior in this site by regulating DA overflow.
CaMKII activity has been shown to enhance AMPH-induced DA efflux both in vitro and in
vivo by directly interacting with the DA transporter [2]. And, indeed, sensitized NAcc DA
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overflow accompanies enhanced AMPH self-administration [27] and manipulations that
prevent induction of the former equally prevent induction of the latter [19,22,23].
It is important, however, to also consider postsynaptic sites of action of CaMKII in enhanced
AMPH self-administration. Previous exposure to AMPH functionally upregulates NAcc
AMPA receptors as evidenced by enhanced NAcc AMPA induced reinstatement compared to
that observed in saline-exposed controls [24]. Evidence suggests that psychostimulant-induced
upregulation of AMPA receptors in NAcc medium spiny neurons is dependent on CaMKII
[1]. Interestingly, this was reported to be the case in NAcc shell but not core. Preliminary
findings have also shown that viral-mediated overexpression of αCaMKII, again in NAcc shell,
leads to enhanced locomotor responding to AMPH in drug-naïve rats [11]. Thus, the present
findings with NAcc shell KN-93 are also consistent with the possibility that CaMKII acts
postsynaptically in this site to mediate enhanced AMPH self-administration. Recently, it was
shown that cocaine reinstatement is dependent on D1 DA receptor-dependent increases in
CaMKII activity (autophosphorylation at Thr286) and phosphorylation of the AMPA receptor
subunit GluR1 at ser831 (a known CaMKII residue) in NAcc shell, leading to the intriguing
possibility that CaMKII may provide a biochemical bridge linking NAcc DA and glutamate
transmission in this site [1]. Whatever the case, the present findings clearly demonstrate an
important role for NAcc shell CaMKII in mediation of enhanced AMPH self-administration
and identify it as a potential target for therapeutic intervention in the treatment of
psychostimulant addiction.
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Figure 1. Injection cannula tip placements in the NAcc shell and core
Black circles represent placements in the NAcc shell; open circles represent placements in the
NAcc core. Line drawings are from Paxinos and Watson [13]. Numbers to the right indicate
mm from bregma.
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Figure 2. Previous exposure to AMPH enhances AMPH self-administration under a PR schedule
of reinforcement
Data are shown as mean (±SEM) number of AMPH infusions obtained on each of the first 4
PR test days. The cumulative number of presses required to obtain these infusions is also shown.
AMPH-exposed rats worked more and consequently obtained significantly more infusions
compared to saline-exposed controls over all 4 PR test days. n=8–9/group.
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Figure 3. Microinjection of KN-93 into the NAcc shell reduces the enhanced AMPH self-
administration observed in sensitized rats
Data are shown as mean (+SEM) number of AMPH infusions obtained on PR test day 4 (PR4)
and the 10 nmol/side KN-93 test day (KN-93). The cumulative number of presses required to
obtain these infusions is also shown. Following the KN-93 microinjection, AMPH-exposed
rats showed a significant reduction in drug intake compared to that observed on PR test day 4.
Inhibiting CaMKII produced no effect in saline-exposed controls. n=8–9/group. *, P<0.05,
significantly different from saline-exposed controls at PR test day 4. †††, P<0.001, significantly
different from PR test day 4. INSET: Microinjection of 1.0 nmol/side KN-93 into the NAcc
shell or 10 nmol/side KN-93 into the NAcc core had no effect on drug intake in AMPH-
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exposed rats. Data are shown as the difference in the number of infusions obtained on the
KN-93 test day from that obtained on PR test day 4 in AMPH-exposed rats tested with KN-93
in the NAcc core (10 nmol/side; n=7), NAcc shell (1.0 nmol/side; n=5), and NAcc shell (10
nmol/side; n=9). †††, P<0.001, significantly different from PR test day 4.
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